Researchers at Kyoto University have made significant strides in the fight against uterine serous carcinoma, one of the most aggressive forms of endometrial cancer. In a collaborative study with Japanese biotech firm Chordia Therapeutics, a novel inhibitor called CTX-439 targeting cyclin-dependent kinase 12 (CDK12) has shown promising results in preclinical models. Published in the prestigious journal Molecular Cancer Therapeutics on March 12, 2026, the research highlights how CTX-439 induces homologous recombination deficiency (HRD), a vulnerability that enhances the effectiveness of PARP inhibitors like olaparib.

This breakthrough comes at a critical time for gynecologic oncology in Japan, where endometrial cancer incidence is rising. According to data from the Japanese Society of Obstetrics and Gynecology, endometrial cancer cases have increased steadily, surpassing cervical cancer as the most common gynecologic malignancy by 2012, with age-adjusted rates climbing from 3.9 per 100,000 in 1990 to 7.6 in 2006. Uterine serous carcinoma (USC), though representing only about 10% of cases, accounts for a disproportionate share of deaths due to its rapid progression and resistance to standard therapies.

Understanding Uterine Serous Carcinoma: A Formidable Foe

Uterine serous carcinoma is a rare but highly lethal subtype of endometrial cancer, often presenting at advanced stages. Unlike the more common endometrioid type, USC is characterized by p53 mutations and shares molecular similarities with high-grade serous ovarian carcinoma (HGSOC), including alterations in homologous recombination (HR) pathways. However, while HGSOC responds relatively well to PARP inhibitors—drugs that exploit HRD by trapping PARP on DNA—USC patients experience limited benefits.

In Japan, USC poses unique challenges. A multi-center study found that 52.8% of cases are diagnosed at stage III-IV, with lymph node metastasis in 28.5%, and preoperative diagnosis is notoriously difficult. Five-year overall survival for high-grade endometrial cancers lags behind lower grades, at around 88% for G3 versus 94.6% for G1. This underscores the urgent need for targeted therapies that address USC's genomic instability without relying solely on traditional chemotherapy.

The Pivotal Role of CDK12 in Cancer Progression

Cyclin-dependent kinase 12 (CDK12), along with its paralog CDK13, plays a crucial role in regulating RNA polymerase II-mediated transcription elongation and termination. By phosphorylating the C-terminal domain (CTD) of RNA polymerase II at serine 2, CDK12 ensures proper expression of long genes, including those vital for DNA damage repair like BRCA1 and BRCA2. In cancers, CDK12 alterations—such as amplification—drive overexpression, promoting tumor survival and resistance to therapies.

Analysis of The Cancer Genome Atlas (TCGA) data revealed that CDK12 amplification is more frequent in USC than in HGSOC, though not directly tied to baseline HRD scores. Importantly, amplified tumors express higher CDK12 levels, correlating with poorer prognosis in USC patients. This positions CDK12 as an actionable target, where inhibition disrupts HR gene transcription, mimicking BRCA mutations and sensitizing cells to DNA-damaging agents.

CDK12's context-dependent role—oncogenic in some cancers, tumor-suppressive in others—highlights the precision required in targeting it, making studies like this from Kyoto University particularly valuable.

CTX-439: Engineering a Selective CDK12/13 Inhibitor

Developed by Chordia Therapeutics, CTX-439 is an orally bioavailable, ATP-competitive small-molecule inhibitor with high selectivity for CDK12 and CDK13. Unlike broader kinase inhibitors, it specifically blocks serine 2 phosphorylation on RNA polymerase II CTD, downregulating DNA repair genes and imposing transcriptional stress on cancer cells. Preclinical data from Chordia's earlier work showed CTX-439's broad antitumor activity across breast, ovarian, and other models, often synergizing with BCL-2 family inhibitors or chemotherapies.

Chordia, a Fujisawa-based biotech, focuses on RNA deregulation—a newly proposed cancer hallmark. While their lead CLK inhibitor CTX-712 is in Phase 1/2 trials in the US for leukemia, CTX-439 remains preclinical but is actively seeking partners for clinical advancement as of early 2026.

The Kyoto University-Chordia Therapeutics Partnership

This study exemplifies fruitful academia-industry collaboration in Japan. Led by Professor Masaki Mandai and corresponding author Mana Taki from Kyoto University's Department of Gynecology and Obstetrics, the research leveraged Professor Kosuke Yusa's expertise in genome engineering at the Institute for Life and Medical Sciences. Supported by AMED's "Practical Research for Innovative Cancer Control" program, it combined Kyoto's clinical PDX models with Chordia's compound.

Mandai's group has a storied history in endometrial cancer research, from minimally invasive surgery surveys to AI-based tertiary lymphoid structure analysis. This partnership not only validates CTX-439 but also accelerates translation from bench to bedside.

Unpacking the Study: Genomics, Cells, and PDX Models

Researchers first mined TCGA data, comparing HRD scores across endometrial subtypes and HGSOC. USC showed elevated HRD versus other endometrioid types but lower than HGSOC. CDK12 amplifications were enriched in USC, linking to high expression and dismal outcomes.

In vitro, USC cell lines with high CDK12 were treated with CTX-439, revealing suppressed BRCA1/2 and other HR genes, γH2AX accumulation (DNA damage marker), and apoptosis. Patient-derived xenograft (PDX) models—gold standard for preclinical prediction—mirrored these effects: CTX-439 halted tumor growth in high-CDK12 PDX, with no toxicity.

Combination arm: CTX-439 plus olaparib (approved in Japan for ovarian/prostate/pancreatic cancers, expanding to endometrial indications) dramatically enhanced efficacy, exploiting synthetic lethality.